Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The burden of neurological diseases in western societies has accentuated the need to develop effective therapies to stop the progression of chronic neurological diseases. Recent discoveries regarding the role of the immune system in brain damage coupled with the development of new technologies to manipulate the immune response make immunotherapies an attractive possibility to treat neurological diseases. The wide repertoire of immune responses and the possibility to engineer such responses, as well as their capacity to promote tissue repair, indicates that immunotherapy might offer benefits in the treatment of neurological diseases, similar to the benefits that are being associated with the treatment of cancer and autoimmune diseases. However, before applying such strategies to patients it is necessary to better understand the pathologies to be targeted, as well as how individual subjects may respond to immunotherapies, either in isolation or in combination. Due to the powerful effects of the immune system, one priority is to avoid tissue damage due to the activity of the immune system, particularly considering that the nervous system does not tolerate even the smallest amount of tissue damage.

Original publication




Journal article


Clinical immunology (Orlando, Fla.)

Publication Date





294 - 305


Department of Neuroscience, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.


T-Lymphocyte Subsets, Stem Cells, Mesenchymal Stem Cells, Animals, Humans, Nervous System Diseases, Multiple Sclerosis, Parkinson Disease, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Autoimmune Diseases, Inflammation, Inflammation Mediators, Cytokines, Immunotherapy, Autoimmunity